Growth Hormone Releasing Peptides (GHRPs) are a class of synthetic peptides that stimulate the release of growth hormone (GH)
from the pituitary gland. They act primarily through the ghrelin receptor (GHSR), mimicking the activity of the natural hunger hormone ghrelin. Common members of this family include GHRP-2, GHRP-6, Ipamorelin, and Hexarelin. These peptides have been studied in research settings for their potential effects on muscle growth, fat metabolism, recovery, and anti-aging. They remain experimental and are not FDA-approved for therapeutic use.
How It Is Used in Research Settings
- Investigated for stimulating pulsatile GH release in metabolic and aging models.
- Studied for supporting muscle repair and lean body mass development.
- Explored for fat metabolism and body composition research.
- Examined for effects on sleep quality, recovery, and overall vitality in preclinical studies.
Proposed Uses (Research Areas)
- Muscle repair and hypertrophy studies.
- Fat metabolism and weight regulation research.
- Aging and regenerative medicine models.
- Endocrine and hormonal regulation studies.
How It Is Dosed in Research Settings
- GHRP-2: Commonly studied at 100–300 mcg subcutaneously, 1–3 times daily.
- GHRP-6: Studied at 100–300 mcg subcutaneously, 1–3 times daily, often noted for increased appetite stimulation.
- Hexarelin: Investigated at 100 mcg daily in research, with strong GH release but potential for desensitization over time.
- Ipamorelin: 200–300 mcg subcutaneously, 1–3 times daily, noted for selective GH release with minimal impact on cortisol or prolactin.
- Cycle length: Protocols vary, but research often runs for 4–12 weeks with rest periods to prevent receptor desensitization.
Important Considerations
- Regulatory status: GHRPs are not FDA-approved for medical use; all applications remain experimental.
- Evidence base: Data is drawn from preclinical studies, small clinical trials, and laboratory models. Large-scale human trials are lacking.
- Safety: Reported research effects include water retention, flushing, increased hunger (especially with GHRP-6), and transient fatigue. Long-term safety in humans is unknown.
Disclaimer
This material is provided for educational purposes only and summarizes published research on GHRPs.
It is not medical advice. GHRPs are experimental, not FDA-approved, and should not be viewed as therapies for medical use.
This peptide is for research use only.